Drug intelligence / Profile preview

elismetrep

Development stage: Phase 3
Lead developer: Kallyope
Modality: Small Molecules
Administration: Oral

Overview

Elismetrep is a small molecule antagonist of the transient receptor potential melastatin 8 (TRPM8) channel. It is being developed for the treatment of migraine, vasomotor symptoms (such as hot flashes), and diabetic neuropathies. The drug was initially developed by Mitsubishi Tanabe Pharma Corporation and is now also being developed by Kallyope. Elismetrep has reached Phase II clinical trials in its main indications, with ongoing studies evaluating its safety and efficacy in these conditions[1][3][4][5].

Other names: 1400699-64-0KIB8V5UR7DKIB-8V5UR7DKIB 8V5UR7D

Targets

TRPM8 (Transient receptor potential cation channel subfamily M member 8)

Beyond the preview

Go deeper on elismetrep.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on elismetrep.

Explore the full profile